依达拉奉治疗老年糖尿病周围神经病变的研究

Effects of edaravone on diabetic peripheral neuropathy in elderly patien

目的观察依达拉奉治疗老年糖尿病周围神经病变(DPN)的临床疗效并探讨其机制。方法老年DPN患者61例,随机分为治疗组33例和常规组28例,两组均予基础治疗,治疗组加用依达拉奉联合前列地尔,常规组予弥可保及前列地尔,疗程均为2周。治疗前后分别判定症状,检查神经传导速度,测定血清MDA、LPO浓度及SOD活力。结果与常规组(53.6%)相比,治疗组症状显著改善(81.8%,P<0.05);神经传导速度增快(P<0.05);常规组血清MDA(6.13±1.46 vs 6.25±1.56μmol.L-1,P>0.05)、LPO(14.82±2.25 vs 15.24±2.49μmol.L-1,P>0.05)、SOD活力(57.14±9.28 vs 55.75±11.21U.mL-1,P>0.05)无明显变化,而治疗组MDA(4.32±1.09 vs 6.15±1.34μmol.L-1,P<0.05)、LPO(10.80±2.37 vs 14.55±2.25μmol.L-1P<0.05)浓度明显降低,SOD活力(76.85±10.76 vs 61.27±12.98U.mL-1P<0.05)显著升高。结论依达拉奉可有效改善DPN患者的临床症状,其机制可能与抗氧化作用有关。

OBJECTIVE To study the clinical ropathy （DPN） and its mechanisms. METHODS ment group and common group randomly. All the effects of edaravone on patients with diabetic peripheral neuTotally 61 elderly patients with DPN were divided into treatpatients were given a basic therapy. Edaravone and alprostadil were administrated to the patients in treatment group for 14 days in addition to the basic therapy. The symptom, nervous conducting speed, serum level of MDA, LPO and SOD activity were determined before and after treatment. RESULTS Compared with common group, the total effective rate in treatment group was significantly bet- ter and the nervous conducting speed was raised notably. Before treatment, SOD activity in DPN patients was lower than those in control group, but serum levels of MDA and LPO were higher. The SOD activity was increased remarkably after edaravone combined with alprostadil treatment, and serum levels of MDA and LPO were decreased. However, the levels of MDA, LPO and SOD activity remained unchanged in common group.CONCLUSION Edaravone could effectively improve the clinical symptoms of patients with DPN, the mechanism of which may be related to antioxidative stress.